The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial
In Chinese people with T2D suboptimally controlled with OADs, once-daily iGlarLixi provided better glycaemic control with BW benefit and lower hypoglycaemia event rates versus IDegAsp.
PDF的下载单位、IP信息已删除
(2025-6-4)
大力的灵雁
Riverchase
无极微光
殷勤的紫槐
eric888
哈哈哈
小小
One
贪玩的秋柔
刚硬小阿博
欣慰猕猴桃
阿申爱乐
盒子
tiptip
带头大哥
缓慢怜菡
cc2004bj
诚心的小x
嘉心糖
Maestro_S
皖公网安备34019202002308
